Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Net Margin (2018 - 2025)

Serina Therapeutics' Net Margin history spans 8 years, with the latest figure at 4287.69% for Q2 2025.

  • For Q2 2025, Net Margin rose 389466.0% year-over-year to 4287.69%; the TTM value through Sep 2025 reached 20168.97%, down 2003064.0%, while the annual FY2024 figure was 31382.14%, 3126521.0% down from the prior year.
  • Net Margin for Q2 2025 was 4287.69% at Serina Therapeutics, down from 39757.14% in the prior quarter.
  • Across five years, Net Margin topped out at 39757.14% in Q4 2024 and bottomed at 63880.0% in Q1 2022.
  • The 5-year median for Net Margin is 8182.35% (2024), against an average of 15497.56%.
  • The largest annual shift saw Net Margin crashed -6370857bps in 2022 before it soared 6038667bps in 2023.
  • A 5-year view of Net Margin shows it stood at 29.17% in 2021, then crashed by -118186bps to 34500.0% in 2022, then soared by 101bps to 247.52% in 2023, then soared by 15962bps to 39757.14% in 2024, then crashed by -111bps to 4287.69% in 2025.
  • Per Business Quant, the three most recent readings for SER's Net Margin are 4287.69% (Q2 2025), 39757.14% (Q4 2024), and 38057.14% (Q3 2024).